At the news
? BULLISHIMPACT 7/10 8-K filed Mar 18, 2026 at 07:07 ET
Arvinas announced positive Phase 1 clinical trial data for ARV-102, showing greater than 50% degradation of LRRK2 in cerebrospinal fluid of Parkinson's disease patients, with the drug well-tolerated across all doses. The company plans to initiate a Phase 1b trial in progressive supranuclear palsy in Q2 2026, with potential for a registrational trial in late 2026.
- ARV-102 demonstrated >50% LRRK2 degradation in CSF at all doses by day 14, maintained through day 28
- Multiple oral doses of ARV-102 (20mg, 40mg, 80mg) were well tolerated with no serious adverse events
- Data presented at AD/PD 2026 conference in Copenhagen
- Company plans to initiate Phase 1b trial in progressive supranuclear palsy in Q2 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access